Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001599298-25-000026
Filing Date
2025-01-06
Accepted
2025-01-06 19:17:50
Documents
4
Period of Report
2025-01-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1736209060.html 4  
1 FORM 4 wk-form4_1736209060.xml 4 6663
2 EX-24 acesano-executedpoafored.htm EX-24 5163
3 acesano-executedpoafored001.jpg GRAPHIC 274112
4 acesano-executedpoafored002.jpg GRAPHIC 35256
  Complete submission text file 0001599298-25-000026.txt   439662
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Issuer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 700 BALTIC CIRCLE, SUITE 716 REDWOOD CITY CA 94065
Business Address
Cesano Alessandra (Reporting) CIK: 0001827015 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36866 | Film No.: 25512981